Search

Your search keyword '"van Marum, Rob"' showing total 576 results
Start Over Author "van Marum, Rob"
576 results on '"van Marum, Rob"'

3. A deprescribing programme aimed to optimise blood glucose-lowering medication in older people with type 2 diabetes mellitus, the OMED2-study: the study protocol for a randomised controlled trial

Author

Andriessen, Charlotte, Blom, Marieke T., van Hoek, Beryl A. C. E., de Boer, Anna W., Denig, Petra, de Wit, G. Ardine, Swart, Karin, de Rooij-Peek, Angela, van Marum, Rob J., Hugtenburg, Jacqueline G., Slottje, Pauline, van Raalte, Daniël, van Bloemendaal, Liselotte, Herings, Ron, Nijpels, Giel, Vos, Rimke C., and Elders, Petra J. M.

Published
2024
Full Text
View/download PDF

4. Optimizing pharmacotherapy and deprescribing strategies in older adults living with multimorbidity and polypharmacy: EuGMS SIG on pharmacology position paper

Author

van Poelgeest, Eveline, Seppala, Lotta, Bahat, Gülistan, Ilhan, Birkan, Mair, Alpana, van Marum, Rob, Onder, Graziano, Ryg, Jesper, Fernandes, Marília Andreia, Cherubini, Antonio, Denkinger, Michael, Eidam, Annette, Egberts, Angelique, Gudmundsson, Aðalsteinn, Koçak, Fatma Özge Kayhan, Soulis, George, Tournoy, Jos, Masud, Tahir, Wehling, Martin, and van der Velde, Nathalie

Published
2023
Full Text
View/download PDF

6. The effect of computerised decision support alerts tailored to intensive care on the administration of high-risk drug combinations, and their monitoring: a cluster randomised stepped-wedge trial

Author

van Balen, Dorieke E.M., Schutte, Peter F., Sigtermans, Marnix J., Kuck, Emile M., van Kan, Erik J.M., van der Steen, Marijke S., Bosma, Liesbeth E., Nowitzky, Ralph O., Beishuizen, Albertus, Movig, Kris L.L., Wesselink, Elsbeth M., Lammers, Rick J.W., Lau, Cedric, Masselink, Joost B., Bosman, Rob J., de Lange, Dylan W., van Marum, Rob J., van der Sijs, Heleen, Franssen, Eric J.F., Kieft, Hans, van den Bergh, Walter M., Bult, Wouter, Renes, Maurits H., de Feiter, Peter W., Wils, Evert-Jan, Hunfeld, Nicole G.M., Mulder, Froukje, Duyvendak, Michiel, Bakker, Tinka, Klopotowska, Joanna E, Dongelmans, Dave A, Eslami, Saeid, Vermeijden, Wytze J, Hendriks, Stefaan, ten Cate, Julia, Karakus, Attila, Purmer, Ilse M, van Bree, Sjoerd H W, Spronk, Peter E, Hoeksema, Martijn, de Jonge, Evert, de Keizer, Nicolette F, and Abu-Hanna, Ameen

Published
2024
Full Text
View/download PDF

8. Deprescribing practices, habits and attitudes of geriatricians and geriatricians-in-training across Europe: a large web-based survey

Author

van Poelgeest, Eveline P., Seppala, Lotta J., Lee, Jihoo M., Bahat, Gülistan, Ilhan, Birkan, Lavan, Amanda H., Mair, Alpana, van Marum, Rob J., Onder, Graziano, Ryg, Jesper, Fernandes, Marília Andreia, Garfinkel, Doron, Guðmundsson, Aðalsteinn, Hartikainen, Sirpa, Kotsani, Marina, Montero-Errasquín, Beatriz, Neumann-Podczaska, Agnieszka, Pazan, Farhad, Petrovic, Mirko, Soulis, George, Vankova, Hana, Wehling, Martin, Wieczorowska–Tobis, Katarzyna, and van der Velde, Nathalie

Published
2022
Full Text
View/download PDF

9. Clinical applicability of quantitative atrophy measures on MRI in patients suspected of Alzheimer’s disease

Author

Ingala, Silvia, van Maurik, Ingrid S., Altomare, Daniele, Wurm, Raphael, Dicks, Ellen, van Schijndel, Ronald A., Zwan, Marissa, Bouwman, Femke, Schoonenboom, Niki, Boelaarts, Leo, Roks, Gerwin, van Marum, Rob, van Harten, Barbera, van Uden, Inge, Claus, Jules, Wottschel, Viktor, Vrenken, Hugo, Wattjes, Mike P., van der Flier, Wiesje M., and Barkhof, Frederik

Published
2022
Full Text
View/download PDF

10. A Systematic Review of the Current Evidence from Randomised Controlled Trials on the Impact of Medication Optimisation or Pharmacological Interventions on Quantitative Measures of Cognitive Function in Geriatric Patients

Author

Pazan, Farhad, Petrovic, Mirko, Cherubini, Antonio, Cruz-Jentoft, Alfonso J., Denkinger, Michael, van der Cammen, Tischa J. M., Stevenson, Jennifer M., Ibrahim, Kinda, Rajkumar, Chakravarthi, Bakken, Marit Stordal, Crome, Peter, Guðmundsson, Adalsteinn, Knol, Wilma, Snijders, Birgitta M. G., O’Mahony, Denis, Serra-Rexach, José Antonio, Soulis, George, van Marum, Rob J., Ziere, Gijsbertus, Mair, Alpana, Burkhardt, Heinrich, Neumann-Podczaska, Agnieszka, Wieczorowska-Tobis, Katarzyna, Fernandes, Marilia Andreia, Gruner, Heidi, van der Velde, Nathalie, and Wehling, Martin

Published
2022
Full Text
View/download PDF

13. Improving medication safety in the Intensive Care by identifying relevant drug-drug interactions - Results of a multicenter Delphi study

Author

Hendriks, S., ten Cate, J., van Balen, D., Duyvendak, M., Karakus, A., Sigtermans, M., Kuck, E.M., Hunfeld, N.G.M., Spronk, P.E., van Kan, H.J.M., van der Steen, M.S., Bosma, B.E., Purmer, I., Kieft, H., Beishuizen, A., Movig, K., Vermeijden, J.W., Mulder, F., Bosman, R.J., Franssen, E.J.F., Wils, E.J., de Feiter, P.W., van den Bergh, W.M., Bult, W., Hoeksema, M., Wesselink, E., Bakker, Tinka, Klopotowska, Joanna E., de Keizer, Nicolette F., van Marum, Rob, van der Sijs, Heleen, de Lange, Dylan W., de Jonge, Evert, Abu-Hanna, Ameen, and Dongelmans, Dave A.

Published
2020
Full Text
View/download PDF

16. Current evidence on the impact of medication optimization or pharmacological interventions on frailty or aspects of frailty: a systematic review of randomized controlled trials

Author

Pazan, Farhad, Petrovic, Mirko, Cherubini, Antonio, Onder, Graziano, Cruz-Jentoft, Alfonso J., Denkinger, Michael, van der Cammen, Tischa J. M., Stevenson, Jennifer M., Ibrahim, Kinda, Rajkumar, Chakravarthi, Bakken, Marit Stordal, Baeyens, Jean-Pierre, Crome, Peter, Frühwald, Thomas, Gallaghar, Paul, Guðmundsson, Adalsteinn, Knol, Wilma, O’Mahony, Denis, Pilotto, Alberto, Rönnemaa, Elina, Serra-Rexach, José Antonio, Soulis, George, van Marum, Rob J., Ziere, Gijsbertus, Mair, Alpana, Burkhardt, Heinrich, Neumann-Podczaska, Agnieszka, Wieczorowska-Tobis, Katarzyna, Fernandes, Marilia Andreia, Gruner, Heidi, Dallmeier, Dhayana, Beuscart, Jean-Baptiste, van der Velde, Nathalie, and Wehling, Martin

Published
2021
Full Text
View/download PDF

17. Impact of Drug Recalls on Patients in The Netherlands: A 5-Year Retrospective Data Analysis

Author

Annema, Pieter A, Derijks, Hieronymus J, Bouvy, Marcel L, van Marum, Rob J, Annema, Pieter A, Derijks, Hieronymus J, Bouvy, Marcel L, and van Marum, Rob J

Abstract

Drug recalls occur frequently and have the potential to impact considerable numbers of patients and healthcare providers. However, in the absence of a comprehensive overview the extent of conducted recalls and their impact on patients remains unknown. To address this, we developed a comprehensive overview of drug recalls affecting patients. We compiled this overview based on the drug recall registrations from the Jeroen Bosch Hospital (JBZ), the University Medical Center Utrecht (UMCU), and the Royal Dutch Pharmacists Association (KNMP). A retrospective data analysis was conducted to identify drug recalls that affected patients. Specifically, we defined these as drug recalls that required patients to actively switch their drug to a different batch or brand of the same drug or to switch to a drug within the same or a different class of drugs. To quantify the impact, we used real-world drug dispensing data. Between January 1, 2017, and December 31, 2021, we identified 48 drug recalls that necessitated patients to make active changes to their medications an estimated 855,000 times. Most of the affected patients (292,000) were required to switch to a different brand of the same drug, whereas in 95,000 cases patients had to switch to a drug from another drug class. Our study suggests that a significant number of patients are affected by drug recalls. Future efforts are needed to elucidate patients' experiences and preferences regarding drug recalls, which could provide valuable insights to aid decision-making by relevant (national) authorities concerning drug recalls.

Published
2024

18. Hospital registration of adverse drug reactions in electronic health records: importance and contribution to pharmacovigilance

Author

Alloush, Roba, van Lint, Jette, van Marum, Rob J., Hermens, Walter W. A. J. J., Jessurun, Naomi T., Alloush, Roba, van Lint, Jette, van Marum, Rob J., Hermens, Walter W. A. J. J., and Jessurun, Naomi T.

Abstract

BackgroundInformation on registered adverse drug reactions (ADRs) in hospitals may provide a large real-world data source that can be used to ensure patients' safety. This study aimed to assess the potential contribution of hospital registration of ADRs in electronic health records (EHR) to pharmacovigilance.Research design and methodsAn observational retrospective descriptive study using data from the Jeroen Bosch Hospital in the Netherlands in 2019. 'Serious and/or severe' and 'previously unknown' ADRs registered systematically in the corresponding field of EHRs were assessed.ResultsADR data concerning 1010 patients were included. In total, 1630 ADRs were registered in EHRs. Fifty-eight serious and/or severe ADRs (5.2%) were registered. Tubulointerstitial nephritis was the most frequently registered severe ADR and was mainly associated with antibacterials for systemic use. A total of 82 previously unknown ADRs (5%) were registered. 'Migraine' and 'chest pain' were the most frequently registered unknown ADRs. Additionally, 25 ADRs (1.5%) were registered that may be attributable to 10 drugs 'under additional monitoring.'ConclusionsHospital registrations of ADRs in EHRs provide information on ADRs, which are challenging to assess during clinical trials. However, improvements are required to optimize this registration before it can serve as a valuable data source for pharmacovigilance purposes.

Published
2024

19. Impact of Drug Recalls on Patients in The Netherlands: A 5-Year Retrospective Data Analysis

Author

Afd Pharmacoepi & Clinical Pharmacology, PECP – Centre for Clinical Therapeutics, Pharmacoepidemiology and Clinical Pharmacology, Annema, Pieter A, Derijks, Hieronymus J, Bouvy, Marcel L, van Marum, Rob J, Afd Pharmacoepi & Clinical Pharmacology, PECP – Centre for Clinical Therapeutics, Pharmacoepidemiology and Clinical Pharmacology, Annema, Pieter A, Derijks, Hieronymus J, Bouvy, Marcel L, and van Marum, Rob J

Published
2024

22. The effect of computerised decision support alerts tailored to intensive care on the administration of high-risk drug combinations, and their monitoring: a cluster randomised stepped-wedge trial

Author

Bakker, Tinka, primary, Klopotowska, Joanna E, additional, Dongelmans, Dave A, additional, Eslami, Saeid, additional, Vermeijden, Wytze J, additional, Hendriks, Stefaan, additional, ten Cate, Julia, additional, Karakus, Attila, additional, Purmer, Ilse M, additional, van Bree, Sjoerd H W, additional, Spronk, Peter E, additional, Hoeksema, Martijn, additional, de Jonge, Evert, additional, de Keizer, Nicolette F, additional, Abu-Hanna, Ameen, additional, van Balen, Dorieke E.M., additional, Schutte, Peter F., additional, Sigtermans, Marnix J., additional, Kuck, Emile M., additional, van Kan, Erik J.M., additional, van der Steen, Marijke S., additional, Bosma, Liesbeth E., additional, Nowitzky, Ralph O., additional, Beishuizen, Albertus, additional, Movig, Kris L.L., additional, Wesselink, Elsbeth M., additional, Lammers, Rick J.W., additional, Lau, Cedric, additional, Masselink, Joost B., additional, Bosman, Rob J., additional, de Lange, Dylan W., additional, van Marum, Rob J., additional, van der Sijs, Heleen, additional, Franssen, Eric J.F., additional, Kieft, Hans, additional, van den Bergh, Walter M., additional, Bult, Wouter, additional, Renes, Maurits H., additional, de Feiter, Peter W., additional, Wils, Evert-Jan, additional, Hunfeld, Nicole G.M., additional, Mulder, Froukje, additional, and Duyvendak, Michiel, additional

Published
2024
Full Text
View/download PDF

23. Impact of Drug Recalls on Patients in The Netherlands: A 5‐Year Retrospective Data Analysis.

Author

Annema, Pieter A., Derijks, Hieronymus J., Bouvy, Marcel L., and van Marum, Rob J.

Subjects
DRUG recall, PATIENTS' attitudes, PATIENT experience, ACADEMIC medical centers, DRUG registration
Abstract

Drug recalls occur frequently and have the potential to impact considerable numbers of patients and healthcare providers. However, in the absence of a comprehensive overview the extent of conducted recalls and their impact on patients remains unknown. To address this, we developed a comprehensive overview of drug recalls affecting patients. We compiled this overview based on the drug recall registrations from the Jeroen Bosch Hospital (JBZ), the University Medical Center Utrecht (UMCU), and the Royal Dutch Pharmacists Association (KNMP). A retrospective data analysis was conducted to identify drug recalls that affected patients. Specifically, we defined these as drug recalls that required patients to actively switch their drug to a different batch or brand of the same drug or to switch to a drug within the same or a different class of drugs. To quantify the impact, we used real‐world drug dispensing data. Between January 1, 2017, and December 31, 2021, we identified 48 drug recalls that necessitated patients to make active changes to their medications an estimated 855,000 times. Most of the affected patients (292,000) were required to switch to a different brand of the same drug, whereas in 95,000 cases patients had to switch to a drug from another drug class. Our study suggests that a significant number of patients are affected by drug recalls. Future efforts are needed to elucidate patients' experiences and preferences regarding drug recalls, which could provide valuable insights to aid decision‐making by relevant (national) authorities concerning drug recalls. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. Association of polypharmacy and hyperpolypharmacy with frailty states: a systematic review and meta-analysis

Author

Palmer, Katie, Villani, Emanuele R., Vetrano, Davide L., Cherubini, Antonio, Cruz-Jentoft, Alfonso J., Curtin, Denis, Denkinger, Michael, Gutiérrez-Valencia, Marta, Guðmundsson, Adalsteinn, Knol, Wilma, Mak, Diane V., O’Mahony, Denis, Pazan, Farhad, Petrovic, Mirko, Rajkumar, Chakravarthi, Topinkova, Eva, Trevisan, Catarina, van der Cammen, Tischa J. M., van Marum, Rob J., Wehling, Martin, Ziere, Gijsbertus, Bernabei, Roberto, Onder, Graziano, and On behalf of the European Geriatric Medicine Society Pharmacology special interest group

Published
2019
Full Text
View/download PDF

29. Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project

Author

Willemse, Eline A.J., van Maurik, Ingrid S., Tijms, Betty M., Bouwman, Femke H., Franke, Andreas, Hubeek, Isabelle, Boelaarts, Leo, Claus, Jules J., Korf, Esther S.C., van Marum, Rob J., Roks, Gerwin, Schoonenboom, Niki, Verwey, Nicolaas, Zwan, Marissa D., Wahl, Simone, van der Flier, Wiesje M., and Teunissen, Charlotte E.

Published
2018
Full Text
View/download PDF

30. Correction to: Current evidence on the impact of medication optimization or pharmacological interventions on frailty or aspects of frailty: a systematic review of randomized controlled trials

Author

Pazan, Farhad, Petrovic, Mirko, Cherubini, Antonio, Onder, Graziano, Cruz-Jentoft, Alfonso J., Denkinger, Michael, van der Cammen, Tischa J. M., Stevenson, Jennifer M., Ibrahim, Kinda, Rajkumar, Chakravarthi, Bakken, Marit Stordal, Baeyens, Jean-Pierre, Crome, Peter, Frühwald, Thomas, Gallaghar, Paul, Guðmundsson, Adalsteinn, Knol, Wilma, O’Mahony, Denis, Pilotto, Alberto, Rönnemaa, Elina, Serra-Rexach, José Antonio, Soulis, George, van Marum, Rob J., Ziere, Gijsbertus, Mair, Alpana, Burkhardt, Heinrich, Neumann-Podczaska, Agnieszka, Wieczorowska-Tobis, Katarzyna, Fernandes, Marilia Andreia, Gruner, Heidi, Dallmeier, Dhayana, Beuscart, Jean-Baptiste, van der Velde, Nathalie, and Wehling, Martin

Published
2021
Full Text
View/download PDF

37. Effects of Pharmacogenetic Screening for CYP2D6 Among Elderly Starting Therapy With Nortriptyline or Venlafaxine: A Pragmatic Randomized Controlled Trial (CYSCE Trial)

Author

van der Schans, Jurjen, Hak, Eelko, Postma, Maarten, Breuning, Laura, Brouwers, Jacobus R.B.J., Ditters, Kaspar, Jansen, Paul A.F., Kok, Rob M., Maring, Jan G., van Marum, Rob, Mulder, Hans, Nanninga, Jaap, Oude Voshaar, Richard C., Risselada, Arne J., Vleugel, Liesbeth, Stek, Max, van Schaik, Ron H.N., Berm, Elizabeth J.J., and Wilffert, Bob

Published
2019
Full Text
View/download PDF

38. Effect of conventional hemodialysis on the apixaban plasma concentration.

Author

Poel, Tim, de Rouw, Nikki, Péquériaux, Nathalie C. V., van de Kerkhof, Daan, Windsant, Annemieke M.A. Vermeulen, van Marum, Rob J., and Kerckhoffs, Angele P. M.

Subjects
APIXABAN, LOW-molecular-weight heparin, BLOOD plasma, HEMODIALYSIS, HEMODIALYSIS patients, DIALYSIS (Chemistry)
Abstract

Purpose: Apixaban is a factor Xa inhibitor used in patients undergoing hemodialysis treatment. The objective of this study is to investigate the effect of hemodialysis on apixaban plasma concentrations. Methods: This observational study is on patients treated with apixaban 2.5 mg twice daily on conventional hemodialysis with standard low‐molecular‐weight heparin (LMWH) anticoagulation (nadroparin 3800–7600 IU). Plasma blood samples were collected before starting dialysis (t1), 2 h after starting dialysis (t2), and directly after dialysis (t3). Apixaban concentration was measured before and after dialysis. Anti‐Xa activity was measured for all three samples. Results: A significant difference was observed between the apixaban concentration before and after dialysis (mean before dialysis 141.03 ng/mL; mean after dialysis 102.71 ng/mL; p = 0.003). Nonetheless, both apixaban plasma concentrations and anti‐Xa levels remained within the reference range. Anti‐Xa levels had a strong correlation with the apixaban concentrations (r = 0.935, p = 0.000). Thus, anti‐Xa activity might be used as a surrogate for apixaban plasma concentration. Conclusion: There seems to be no need for dose adjustments of apixaban; co‐administration of LMWH next to apixaban might also be unnecessary. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

42. Psychotropic drug treatment for agitated behaviour in dementia: what if the guideline prescribing recommendations are not sufficient? A qualitative study

Author

Dijk, Margaretha T, Tabak, Sarah, Hertogh, Cees M P M, Kok, Rob M., van Marum, Rob J, Zuidema, Sytse U, Sizoo, Eefje M, Smalbrugge, Martin, Elderly care medicine, APH - Aging & Later Life, APH - Quality of Care, and Life Course Epidemiology (LCE)

Subjects
Psychotropic Drugs, Aging, General Medicine, non-guideline treatment, decision making, older people, agitated behaviour in dementia, Physicians, qualitative, Quality of Life, focus group, Humans, Dementia, Practice Patterns, Physicians', Geriatrics and Gerontology, Aged
Abstract

Background Agitation is a common challenging behaviour in dementia with a negative influence on patient’s quality of life and a high caregiver burden. Treatment is often difficult. Current guidelines recommend restrictive use of psychotropic drug treatment, but guideline recommendations do not always suffice. Objective To explore how physicians decide on psychotropic drug treatment for agitated behaviour in dementia when the guideline prescribing recommendations are not sufficient. Methods We conducted five online focus groups with a total of 22 elderly care physicians, five geriatricians and four old-age psychiatrists, in The Netherlands. The focus groups were thematically analysed. Results We identified five main themes. Transcending these themes, in each of the focus groups physicians stated that there is ‘not one size that fits all’. The five themes reflect physicians’ considerations when deciding on psychotropic drug treatment outside the guideline prescribing recommendations for agitated behaviour in dementia: (1) ‘reanalysis of problem and cause’, (2) ‘hypothesis of underlying cause and treatment goal’, (3) ‘considerations regarding drug choice’, (4) ‘trial and error’ and (5) ‘last resort: sedation’. Conclusion When guideline prescribing recommendations do not suffice, physicians start with reanalysing potential underlying causes. They try to substantiate and justify medication choices as best as they can with a hypothesis of underlying causes or treatment goal, using other guidelines, and applying personalised psychotropic drug treatment.

Published
2022
Full Text
View/download PDF

45. Personal Continuity and Appropriate Prescribing in Primary Care.

Author

te Winkel, Marije T., Damoiseaux-Volman, Birgit A., Abu-Hanna, Ameen, Lissenberg-Witte, Birgit I., van Marum, Rob J., Schers, Henk J., Slottje, Pauline, Uijen, Annemarie A., Bont, Jettie, and Maarsingh, Otto R.

Abstract

PURPOSE Personal continuity between patient and physician is a core value of primary care. Although previous studies suggest that personal continuity is associated with fewer potentially inappropriate prescriptions, evidence on continuity and prescribing in primary care is scarce. We aimed to determine the association between personal continuity and potentially inappropriate prescriptions, which encompasses potentially inappropriate medications (PIMs) and potential prescribing omissions (PPOs), by family physicians among older patients. METHODS We conducted an observational cohort study using routine care data from patients enlisted in 48 Dutch family practices from 2013 to 2018. All 25,854 patients aged 65 years and older having at least 5 contacts with their practice in 6 years were included. We calculated personal continuity using 3 established measures: the usual provider of care measure, the Bice-Boxerman Index, and the Herfindahl Index. We used the Screening Tool of Older Person's Prescriptions (STOPP) and the Screening Tool to Alert doctors to Right Treatment (START) specific to the Netherlands version 2 criteria to calculate the prevalence of potentially inappropriate prescriptions. To assess associations, we conducted multilevel negative binomial regression analyses, with and without adjustment for number of chronic conditions, age, and sex. RESULTS The patients' mean (SD) values for the usual provider of care measure, the Bice-Boxerman Continuity of Care Index, and the Herfindahl Index were 0.70 (0.19), 0.55 (0.24), and 0.59 (0.22), respectively. In our population, 72.2% and 74.3% of patients had at least 1 PIM and PPO, respectively; 30.9% and 34.2% had at least 3 PIMs and PPOs, respectively. All 3 measures of personal continuity were positively and significantly associated with fewer potentially inappropriate prescriptions. CONCLUSIONS A higher level of personal continuity is associated with more appropriate prescribing. Increasing personal continuity may improve the quality of prescriptions and reduce harmful consequences. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

50. A Systematic Review of the Current Evidence from Randomised Controlled Trials on the Impact of Medication Optimisation or Pharmacological Interventions on Quantitative Measures of Cognitive Function in Geriatric Patients

Author

MS Geriatrie, Circulatory Health, Pazan, Farhad, Petrovic, Mirko, Cherubini, Antonio, Cruz-Jentoft, Alfonso J., Denkinger, Michael, van der Cammen, Tischa J.M., Stevenson, Jennifer M., Ibrahim, Kinda, Rajkumar, Chakravarthi, Bakken, Marit Stordal, Crome, Peter, Guðmundsson, Adalsteinn, Knol, Wilma, Snijders, Birgitta M.G., O’Mahony, Denis, Serra-Rexach, José Antonio, Soulis, George, van Marum, Rob J., Ziere, Gijsbertus, Mair, Alpana, Burkhardt, Heinrich, Neumann-Podczaska, Agnieszka, Wieczorowska-Tobis, Katarzyna, Fernandes, Marilia Andreia, Gruner, Heidi, van der Velde, Nathalie, Wehling, Martin, MS Geriatrie, Circulatory Health, Pazan, Farhad, Petrovic, Mirko, Cherubini, Antonio, Cruz-Jentoft, Alfonso J., Denkinger, Michael, van der Cammen, Tischa J.M., Stevenson, Jennifer M., Ibrahim, Kinda, Rajkumar, Chakravarthi, Bakken, Marit Stordal, Crome, Peter, Guðmundsson, Adalsteinn, Knol, Wilma, Snijders, Birgitta M.G., O’Mahony, Denis, Serra-Rexach, José Antonio, Soulis, George, van Marum, Rob J., Ziere, Gijsbertus, Mair, Alpana, Burkhardt, Heinrich, Neumann-Podczaska, Agnieszka, Wieczorowska-Tobis, Katarzyna, Fernandes, Marilia Andreia, Gruner, Heidi, van der Velde, Nathalie, and Wehling, Martin

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results